Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment

NCT07314164

Status	RECRUITING
Sponsor	Ipsen
Enrollment	150 participants

Key Eligibility Criteria

Inclusion (6)

- Participants can join the study if they meet all of the following conditions:
- Are 18 years or older and able to give informed consent.
- Have a physician-initiated decision to start treatment with cabozantinib for neuroendocrine tumors (NETs), made before joining the study.
- Have unresectable or metastatic, well-differentiated pancreatic (pNET) or extra-pancreatic neuroendocrine tumors (epNET).
- Have already received at least one prior systemic therapy, other than somatostatin analogues.

... and 1 more (see full listing online)

Exclusion (3)

- Participants cannot join the study if:
- They are currently participating in an interventional clinical trial, or have done so within the last 3 months before joining this study.
- They have a contraindication to cabozantinib treatment, based on the product's official prescribing information.

Locations (28 total)

Medizinische Universitaet Graz, Graz, Austria
MVZ am Klinikum Aschaffenburg, Aschaffenburg, Germany
DRK Kliniken Berlin, Berlin, Germany
... and 25 more locations

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.